Word count: 3697 2 ABSTRACT Purpose: Age-related Macular Degeneration (AMD) has a strong genetic component with a major locus at 1q31, including the complement factor H gene (CFH). Detailed analyses of this locus have demonstrated the existence of one SNP haplotype block, carrying the CFH-402His allele, which confers increased risk to AMD, and two protective SNP haplotypes, one of them carrying a deletion of the CFHR1 and CFHR3 genes (Δ CFHR3-CFHR1 ). The purpose of these studies was to evaluate the contribution of newly described CFHR1 alleles to the association of the 1q31 locus with AMD.
INTRODUCTION
Age-related macular degeneration (AMD) is the most common cause of visual disability in the elderly in developed countries 1 . AMD is a multifactorial disease, influenced by age, ethnicity and a combination of environmental and genetic risk factors 2 . Genetic predisposition in AMD has been suggested based on familial segregation and twins studies. Several candidate genes with a relatively minor contribution and two major susceptibility loci (1q31, CFH/CFHR1/CFHR3; 10q26, HTRA1/ARMS2) that independently contribute to AMD disease risk have been identified by candidate region studies and whole genome association analyses [3] [4] [5] [6] [7] [8] [9] [10] .
The 10q26 locus includes two nearby genes, ARMS2 (age-related maculopathy susceptibility 2, also known as LOC387715) 11 and HTRA1 (high-temperature requirement factor A1) 11 . The most studied SNP at this locus is rs10490924, which causes the Ala69Ser amino acid substitution in ARMS2, a protein located in the ellipsoid, a mitochondria-concentrated part of human photoreceptor cells. The riskassociated allele ARMS2-69Ser is in strong linkage disequilibrium with a genetic variant resulting from a combination of a deletion and insertion (*372_815delins54) in the 3' untranslated region of the ARMS2 mRNA, which affects the stability of the ARMS2 mRNA and supports a role for ARMS2 in AMD pathogenesis 11 .
Several independent studies have shown that the CFH-402His allele (rs1061170), at the CFH locus in 1q31, confers a significantly increased risk to AMD with an odds ratio (OR) between 2.1 and 7.4 3, [5] [6] [7] . The association of CFH with AMD strengthened the implication of the complement system in the pathogenesis of AMD 5 and prompted subsequent candidate gene approaches that resulted in the identification of additional associations of complement genes with AMD 4, 9-10, 12-15 . As a whole, these genetic data reinforced the concept that complement disregulation is a major player in AMD pathogenesis. This conclusion is supported by the functional analysis of the AMD-associated SNPs in the CFH 16 , CFB 17 and C3 18 genes. The CFH Tyr402His polymorphism has also been found to have functional implications. Notably, it alters the binding specificity of factor H for different glycosaminoglycans [19] [20] and decreases its binding to retinal pigment epithelial cells 21 and Bruch membrane 22 . However, the physiological relevance of these observations is still unclear.
Within the CFH gene, downstream of the Tyr402His polymorphism, there are three polymorphisms, a synonymous SNP in exon 11 (rs2274700) and two intronic SNPs (rs1410996 and rs7535263), showing stronger association with disease susceptibility than the CFH-402His variant [14] [15] . These polymorphisms and the CFH 402His variant form part of the same CFH haplotype conferring increased risk to AMD (haplotype H1) 23 . Two additional haplotypes in CFH gene (haplotypes H2 and H4) are markedly decreased in AMD and therefore have been described associated with lower risk to AMD 13, 15, 24 . CFH haplotype H2 carries the Ile62 factor H variant showing increased complement regulatory activity 16 , which likely confers lower risk to AMD by reducing complement activation. CFH haplotype H4 is also associated with decreased risk of AMD 13, 25 . Interestingly, this CFH haplotype is also unique because it carries a deletion of the CFHR1 and CFHR3 genes (Δ CFHR3-CFHR1 ) 13 . Although it has been indicated that CFHR1 and CFHR3 proteins have the potential to compete with factor H and interfere its complement regulatory activity, the potential benefit of the absence of CFHR1 and CFHR3 proteins is still puzzling as these two proteins are considered complement regulators 26 . Recently it has been proposed that complement activity is determined by a homeostatic balance between CFHR1, CFHR3 and factor H and that loss of CFHR1 and CFHR3, affecting local factor H binding, may increase local factor 
RESULTS
The CFHR1*A allele is strongly associated with AMD.
We have recently described a novel polymorphism of the CFHR1 gene with two alleles, CFHR1*A and CFHR1*B, encoding CFHR1 proteins that present different degree of similarity to factor H ( Figure 1 ). The CFHR1*B allotype, with greater sequence similarity to factor H is strongly associated with atypical hemolytic uremic syndrome (aHUS), perhaps suggesting that increased competition between CFHR1*B and factor H decreases protection of cellular surfaces against complement damage 29 . To study whether this novel CFHR1 polymorphism also influences predisposition to AMD we genotyped our AMD cohort and the matched control population for the CFHR1
allotypes. In addition, we included in these studies the analysis of other polymorphisms that had been previously associated with AMD 3-10, 13 (see Materials and Methods). The allelic frequencies of each of these polymorphisms were determined and compared between the two groups ( Table 1 ). In agreement with previous studies we have found strong positive associations between the alleles CFH-402His, CFH-c.2237-543G and
ARMS2-69Ser and AMD, and a strong protective association of CFH-62Ile, CFB-9His
and CFB-32Gln/Trp with AMD. C3-102Gly, previously found associated with AMD, shows a similar positive trend in our population that was not statistically significant.
Interestingly, the three CFHR1 alleles show very distinct associations with AMD. A very strong and significant association was found between AMD and the CFHR1 allotype CFHR1*A (OR= 2.08, 95% CI 1.59-2.73), whereas no significant differences in the frequency of the CFHR1*B allele were found between AMD patients and controls (0.34 vs 0.38). As previously reported, the third CFHR1 allele Δ CFHR3-CFHR1 shows a very significant protective effect for AMD (OR= 0.34, 95% CI 0.23-0.50) ( Table 1 ).
The associations between the six CFHR1 genotypes and AMD are depicted in Table 2 . heterozygote carriers. In fact, the frequency of these heterozygotes is significantly decreased in AMD indicating that this genotype protects against AMD (OR=0.40, 95%
CI 0.24-0.69). Therefore, the CFHR1Δ CFHR3-CFHR1 allele has a dominant effect over the CFHR1*A allele. The CFHR1 genotype data shown in Table 2 confirms the neutral role of the CFHR1*B allele in AMD. In agreement with previous reports, the CFHR1Δ CFHR3-CFHR1 homozygote genotype has a strong AMD protective effect (OR= 0.48, 95% CI 0.17-1.37), although it is not statistically significant in our study due to the reduced size of our control and patient cohorts.
CFHR1*A is in strong linkage disequilibrium with CFH 402His.
Strong linkage disequilibrium across the CFH-CFHR3-CFHR1 genes has been described earlier 24, 27 . Consistently with these findings we found strong linkage disequilibrium between SNPs in the CFH gene and the CFHR1 alleles in both the AMD and control populations (Figure 2 ), which further illustrate that the CFH haplotypes associated with AMD extend away from the CFH gene to include the CFHR1 alleles.
Comparison of the frequencies for these extended haplotypes (including the CFH, CFHR3 ( Figure 2 ). It is also interesting that the CFH-402His and CFHR1*A alleles shows much stronger linkage disequilibrium in controls than in AMD patients (0.90 vs 0.78) ( Table   3 ). This could be related to the slight increase of some minoritary haplotypes carrying CFHR1*A without CFH-402His in the AMD cohort ( Figure 3 ). If confirmed, these data would emphasize the relevance of CFHR1 for the association of this extended CFH haplotype with AMD.
Usefulness of the CFHR1 genotypes in the calculation of AMD risk scores and probability of AMD development.
To evaluate the relevance of the CFHR1 genotypes in assessing the predictability of AMD development, we compared two alternative models including different sets of polymorphisms associated with AMD in the Spanish population. Model 1, considers the CFH Tyr402His genotypes together with those of the CFB Leu9His, CFB Arg32Gln/Trp, ARMS2 Ala69Ser and Δ CFHR3-CFHR1 polymorphisms. Model 2, is based on the genotypes at the triallelic locus CFHR1 in addition to the genotypes of the CFB Leu9His, CFB Arg32Gln/Trp and ARMS2 Ala69Ser polymorphisms. We have used multivariate logistic regression analysis and ROC statistics for the calculation of the AMD risk scores and the probability of AMD development using these two models (Table 4 ; Figure 3 ). Regression coefficients (risk scores) for all the genotypes were determined comparing their frequencies in cases and controls for the two models (Table   4 ). To assess the cumulative AMD risk scores (Z) for each individual we simply added the risk scores (α and β regression coefficients) obtained in the multivariate logistic regression analysis (Table 4) Methods). In general, cases had higher probabilities than controls. To illustrate this better we categorized the probabilities in four groups of risk: very low (VL; P<25%), low (L; 25%>P<50%), high (H; 50%>P<75%) and very high (VH; P>75%). As expected, the controls with no sign of AMD tend to cluster in the low risk groups, whereas our AMD cases fell predominantly into the high-risk groups (Figure 3c ). 
DISCUSSION
Here we report that CFHR1*A, a recently described allele in the CFHR1 gene, is over- However, the physiological relevance of these observations is still unclear. In contrast, the factor H 62Ile variant, showing increased complement regulatory activity, likely confers lower risk to AMD by reducing complement activation 16 .
In close proximity to CFH, within the extended CFH haplotypes, are CFHR1 and CFHR3, two genes coding for proteins showing sequence and structural homology to factor H (Figure 1 ). CFHR3 and CFHR1 are both complement regulators that compete with factor H for binding to C3b. CFHR1 acts downstream of factor H and inhibits the C5-convertase and the lytic pathway, while CFHR3 acts as a cofactor for factor I in inactivating C3b [26] [27] . Based on the reported functional activities of CFHR1 and CFHR3
it seems paradoxical that the loss of these two complement regulators strongly protects against AMD. On the other side, it has been consistently found that Δ CFHR3-CFHR1 is an independent protective factor for AMD, which suggest that CFHR3 and/or CFHR1 protein function confers risk to AMD.
The concept that CFHR1 confers risk to AMD is further supported by our findings that 
Conclusions and limitations of the study.
We show here that the CFHR1*A allele is strongly associated with AMD. These novel data and previous studies in our laboratory 29 demonstrate a differential association of the two major CFHR1 allotypes, CFHR1*A and CFHR1*B, with AMD and aHUS, respectively, which suggests that CFHR1 play a relevant role in these pathologies. In fact, and despite CFHR1*A is in strong linkage disequilibrium with the CFH-402His allele, our data support that CFHR1*A is a strong candidate within the mayor risk haplotype at 1q32 for being responsible for the association with AMD. However, our study has limitations. It includes a relatively small case-control cohort, which prevent us to determine whether the CFHR1*A variant remains significantly associated with AMD after removing the CFH-402His-carrying haplotypes. Additional studies and further understanding of the functional activities of CFHR1, including the potential differences between the CFHR1*A and CFHR1*B allotypes, may help to determine whether the CFHR1 genotypes are more relevant to AMD than the CFH Tyr402His variant.
Meanwhile, we have tested the usefulness of CFHR1 to generate models of disease risk and demonstrated that the CFHR1 genotypes provide meaningful predictive values for the development of AMD.
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